No annual data found.
Hemab Therapeutics reports Q1 2026 results with $22.7M net loss, completed $346.7M IPO in May 2026, and received Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia
“With the successful completion of our IPO, our team remains focused on advancing sutacimig toward pivotal trials, advancing HMB-002, while continuing to expand our pipeline.”
| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | 2026-05-21 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Purchase | 996 | $24.94 | $25K | 6.38M | View | |
| 2026-05-19 | 2026-05-21 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Purchase | 3,802 | $24.97 | $95K | 6.38M | View | |
| 2026-05-12 | 2026-05-14 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Purchase | 6,387 | $24.90 | $159K | 6.37M | View | |
| 2026-05-11 | 2026-05-11 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Purchase | 39.9K | $24.81 | $989K | 6.37M | View | |
| 2026-05-08 | 2026-05-11 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Purchase | 1,483 | $24.98 | $37K | 6.33M | View |
Informational purposes only, not investment advice.